Kynurenic acid levels are increased in the CSF of Alzheimer's disease patients
González-Sánchez, Marta (Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas)
Jiménez, Javier (Universidad de Alcalá)
Narváez García, Arantzazu (Universidad de Alcalá)
Antequera, Desiree (Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas)
Llamas-Velasco, Sara (Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas)
Herrero San-Martín, Alejandro (Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas)
Molina Arjona, Jose Antonio (Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas)
Lopez de Munain, Adolfo (Biodonostia Osasun Ikerketako Institutura (País Basc))
Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau)
Marco, María Pilar (Centro de Investigación Biomédica en Red (CIBER) de Bioingeniería. Biomateriales y Nanomedicina (CIBER-BBN))
Rodríguez-Núñez, Montserrat (Centro de Investigación Biomédica en Red (CIBER) de Bioingeniería. Biomateriales y Nanomedicina (CIBER-BBN))
Pérez-Martínez, David Andrés (Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas)
Villarejo-Galende, Alberto (Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas)
Bartolome, Fernando (Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas)
Domínguez, Elena (Universidad de Alcalá)
Carro, Eva M. (Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas)
Universitat Autònoma de Barcelona

Date:	2020
Abstract:	Kynurenic acid (KYNA) is a product of the tryptophan (TRP) metabolism via the kynurenine pathway (KP). This pathway is activated in neurodegenerative disorders, such as Alzheimer's disease (AD). KYNA is primarily produced by astrocytes and is considered neuroprotective. Thus, altered KYNA levels may suggest an inflammatory response. Very recently, significant increases in KYNA levels were reported in cerebrospinal fluid (CSF) from AD patients compared with normal controls. In this study, we assessed the accuracy of KYNA in CSF for the classification of patients with AD, cognitively healthy controls, and patients with a variety of other neurodegenerative diseases, including frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), and progressive supranuclear palsy (PSP). Averaged KYNA concentration in CSF was higher in patients with AD when compared with healthy subjects and with all the other differentially diagnosed groups. There were no significant differences in KYNA levels in CSF between any other neurodegenerative groups and controls. These results suggest a specific increase in KYNA concentration in CSF from AD patients not seen in other neurodegenerative diseases.
Grants:	Instituto de Salud Carlos III PI18/00118 Ministerio de Ciencia e Innovación CTQ2011-29163-C03-01
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Alzheimer's disease ; Amyloid-β ; Biomarkers ; Cerebrospinal fluid ; Kynurenine pathway ; Tau protein
Published in:	Biomolecules, Vol. 10 Núm. 4 (april 2020) , p. 571, ISSN 2218-273X

DOI: 10.3390/biom10040571
PMID: 32276479

15 p, 1.2 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles